Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 85,859 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Brain Activity
Interventions: Methylene Blue (USP grade, 280mg oral), Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab, Tucatinib; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more

Conditions: Atopic Dermatitis
Interventions: pimecrolimus, topical medical device; Drug · Device
Lead sponsor: Emer, Jason, M.D.; Individual
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes, Heart Disease
Interventions: Vitamin E, Dummy pills; Dietary Supplement · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 30 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rotator Cuff Tear
Interventions: Robotic Therapy; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injury
Interventions: C-Brace II, Traditional Care KAFO intervention; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myeloid Malignancies
Interventions: Dexamethasone, Cyclophosphamide, Fludarabine, Decitabine, TGFBR2 KO CAR27/IL-15 NK cells; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms
Interventions: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Major Depressive Disorder
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 78
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more

Conditions: Leukemia
Interventions: aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Early Childhood Development, Behavior Problems
Interventions: Infant Behavior Program (IBP), Enhanced Pediatric Primary Care (EPPC); Behavioral · Other
Lead sponsor: Florida International University; Other
Eligibility: 12 Months to 18 Months
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Traumatic Brain Injury, Ketogenic Dieting
Interventions: Ketogenic diet; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Skin Aging
Interventions: HyaCera™, Placebo; Dietary Supplement
Lead sponsor: Natals, Inc. dba Ritual; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Ornithine Transcarbamylase Deficiency
Interventions: No Intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Dry Eye
Interventions: PEG-400 based artificial tear, Systane; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Tumors
Interventions: Bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 6
States / cities: Tucson, Arizona • Santa Monica, California • Memphis, Tennessee + 3 more

Conditions: Human Mammary Carcinoma
Interventions: AEG35156; Drug
Lead sponsor: Aegera Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more

Conditions: Glaucoma, Ocular Surface Disease
Interventions: Xiidra (Lifitegrast ophthalmic solution) 5%; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza Dose 1, Afrezza Dose 2; Combination Product
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Escondido, California • Walnut Creek, California

Conditions: Healthy
Interventions: AG120, Itraconazole; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension
Interventions: Valsartan/Hydrochlorothiazide, HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

Arm Robotics in Musculoskeletal Rehabilitation

C-Brace II Spinal Cord Injury

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

The PANTHERS (Parents and iNfants Together in Home-based Early Remote Services) Project

Ketogenic Diet for Traumatic Brain Injury

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women

Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency

Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Afrezza® Dosing Optimization Study

Drug-Drug Interaction Study of AG120 in Healthy Subjects

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension